A BETTER FUTURE FOR PATIENTS WITH BLADDER CANCER USING ADVANCED TECHNOLOGIES INCLUDES A VITAL ROLE FOR BLUE LIGHT CYSTOSCOPY WITH HEXVIX®

Oslo, Norway, February 8th 2017, Photocure ASA announced today a publication in the Scandinavian Journal of Urology, describing a vision for improving outcomes for patients with non-muscle-invasive bladder cancer (NMIBC), and the significant role that blue light cystoscopy (BLC) with Hexvix® plays in achieving it.

Read the full abstract by clicking here.

“We are pleased that such a renowned group of urologists can see a brighter future for patients suffering from NMIBC, a disease with high recurrence rates, and many costly and invasive follow up procedures and treatments. BLC with Hexvix® clearly has a leading role in this future, especially as its application is expanding beyond the operating room to the outpatient clinic using flexible cystoscopes” says Kjetil Hestdal, MD, PhD, President and CEO, Photocure ASA.

In the article the authors advocate a future where advances in molecular diagnostics, imaging and resection techniques will drive a paradigm shift to personalized care, thereby reducing the burden of disease. This would mean that patients with the poorest prognosis will receive the most aggressive treatment, while low-risk patients are not subjected to unnecessary procedures. Such a holistic and dynamic approach is crucial to curb healthcare expenditure, facilitate adherence to follow-up schedules and improve outcomes in bladder cancer, one of the most frequent and costly cancers.

The authors conclude that their vision is achievable and the role of improved technologies such as BLC with Hexvix® is vital in achieving that goal.

About Photocure

Photocure, headquartered in Oslo Norway, is a specialty pharmaceutical company and world leader in photodynamic technology. Based on its unique proprietary Photocure Technology® platform, Photocure develops and commercializes highly selective and effective solutions in disease areas with high-unmet medical need, such as bladder cancer, HPV and precancerous cervical lesions, and skin conditions. Photocure’s aim is to provide solutions which can improve health outcomes for patients worldwide. The company is listed on the Oslo Stock Exchange (OSE: PHO). Information about Photocure is available at www.photocure.com.

Disclaimer
All trademarks mentioned in this release are protected by law and are registered trademarks of Photocure ASA

This press release may contain product details and information which are not valid, or a product is not accessible, in your country. Please be aware that Photocure does not take any responsibility for accessing such information which may not comply with any legal process, regulation, registration or usage in the country of your origin.

References
1. Globocan. Incidence/mortality by population.  Available at:
http://globocan.iarc.fr/Pages/bar_pop_sel.aspx
2. Leal et al, Eur Urol 2016; 69: 438-447
3. Babjuk M, Burger M, Zigeuner R, Shariat SF, van Rhijn BW, Compérat E, et al. EAU Guidelines on
non-muscle-invasive bladder cancer (Ta, T1 and CIS). Eur Urol. 2016 Guidelines Edition:1-40.
3. Sievert KD et al. World J Urol 2009;27:295-300
4. Bladder Cancer. American Cancer Society.
http://www.cancer.org/acs/groups/cid/documents/webcontent/003085-pdf.pdf. Accessed April 2016.
5. Bladder Cancer. American Cancer Society.
http://www.cancer.org/acs/groups/cid/documents/webcontent/003085-pdf.pdf. Accessed April 2016.